Mendus AB (publ) has carried out a capital raise totalling approximately SEK 317 million, comprised of a directed issue of shares and warrants to Flerie of approximately SEK 90 million, in combination with a rights issue of units of approximately SEK 227 million. 

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. The company is  leveraging its expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm.

Pareto Securities acted as Sole Manager and Bookrunner. Baker McKenzie acted as legal advisor to Pareto Securities with a capital markets team consisting of Joakim Falkner and Johanna Flink.

Explore Our Newsroom